PharmaBoardroom

ICER Strikes Again: Scandal Time?

The US drug-price watchdog, The Institute for Clinical & Economic Review (ICER) recently issued a “Report on Unsupported Price Increases“,…

Regulatory & Legal Affairs: Two Growth Areas for Pharma

Within the pharmaceutical space, Eurasia Group's Aditya Bhattacharji expects politics to drive significant changes in regulatory and legal affairs. He…

Bridging the Innovation Gap with AI

Professor Jackie Hunter looks at why the pharmaceutical industry has been so slow to adopt artificial intelligence-based technologies and makes a…

US FDA CBD Approvals Set to Soar

Sophia Ononye outlines the history of cannabis as a medicine in the US and, following the first FDA approval of a cannabis-derived drug product in…

Countering Algeria’s Diabetes Epidemic, With Pharmacists?

Yacine Sellam examines how pharmacists in Algeria can follow the lead of their US counterparts and play a greater role in patients' diabetes…

After the Prescription Is Written, Another Challenge: Abandonment

The AAM’s Chip Davis tackles the issue of abandonment within US healthcare and proposes three measures to boost competition, thereby lowering drug…

AI in Healthcare M&A: On the Rise

David H. Crean, managing director for Objective Capital Partners, highlights the latest trends in mergers and acquisition (M&A) activities…

Recent Developments in Latvian Pharma

Dr Valters Bolevics, CEO of the Association of International Research-based Pharmaceutical Manufacturers (SIFFA) in Latvia, gives an overview of…

AI in APAC Healthcare: Building the Foundations

Vishal Doshi looks at how AI is already revolutionising healthcare in Asia-Pacific and the work still to be done on the foundational elements –…

The Three Top Political Issues for Big Pharma

Eurasia Group’s Aditya Bhattacharji and Sarah Hassan identify and unpack the top three political and policy issues that multinational pharmaceutical…

AI: The Time is Right for a New Pharma Business Model

Dr Kamala Maddali looks at how artificial intelligence is currently being utilized across the healthcare spectrum and why the time is now for Big…

From Hype to Health: Delivering on the Promise of AI in Biopharma

Krishna Cheriath, chief data officer at BMS, outlines the ways in which AI is already transforming the delivery of healthcare, what modern biopharma…

Tagged with Opinion